Clinical trials: Oxycodone
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Recreational Drug Use
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)
The purpose of this study is to examine the abuse potential and pharmacokinetics of PF614 compared with a non-abuse deterrent, commercially available, immediate release (IR) oxycodone hydrochloride (HCl) formulation and placebo.
- Trial name
- NCT05567354
- Testing
- PF614, Oxycodone
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Moderate to Severe Idiopathic RLS With Daytime Symptoms
Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms
The primary objective for the 12-week Titration-/Maintenance Period is: To demonstrate superior efficacy of OXN PR compared to PLA in the improvement of symptom severity of RLS.
- Trial name
- NCT01112644
- Testing
- Oxycodone naloxone prolonged release tablets (OXN PR)
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 205 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Healthy
Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)
PF614 is an oxycodone prodrug that is designed for extended-release of oxycodone comparable to OxyContin. This Single Ascending Dose (SAD) study is designed to assess the safety and pharmacokinetics (PK) of PF614 in comparison to…
- Trial name
- SAD (NCT02454712)
- Testing
- PF614, Oxycodone extended-release, Naltrexone Hydrochloride
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ensysce Biosciences
Cancer Pain
An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.
The purpose of this study is to compare of difference in NRS scores from baseline to the completion of treatment (5 days) in patients with administration of morphine sulfate versus oxycodone hydrochloride.
- Trial name
- SWITCH (NCT02660229)
- Testing
- Oxycodone Hydrochloride, Morphine Sulphate
- Where
- South Korea
- Volunteers
- 66 people
- Sponsor
- Mundipharma Korea Ltd
Chronic Pain
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN…
- Trial name
- NCT02880475
- Testing
- OXN PR tablet
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Other Acute Postoperative Pain
Oxycodone Hydrochloride Injection in the Postoperative Pain Relieving Treatment
To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA) in the pain relieving treatment during 48h postoperative period, by comparing with morphine i.v. PCA.
- Trial name
- NCT01304134
- Testing
- Oxycodone, Morphine
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Healthy
To Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (40 mg) relative to the original OxyContin® (OXY) formulation (40 mg) in the fasted state.
- Trial name
- NCT01101165
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Moderate-severe Pain
Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
- Trial name
- NCT02680847
- Testing
- ALO-02
- Where
- 16 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pfizer
Postoperative Pain
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
- Trial name
- NCT00092313
- Testing
- MK0966, rofecoxib, Comparator: oxycodone and acetaminophen
- Volunteers
- 271 people
- Sponsor
- Merck Sharp & Dohme LLC
Osteoarthritis
A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee
The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.
- Trial name
- NCT00483977
- Testing
- Oxycodone, PF-000592379
- Where
- 21 sites in United States
- Volunteers
- 113 people
- Sponsor
- Pfizer
Moderate-to-severe Chronic Noncancer Pain
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
- Trial name
- NCT02603705
- Testing
- Oxycodone extended-release
- Where
- 39 sites in United States
- Volunteers
- 281 people
- Sponsor
- Egalet Ltd
Pain Management
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)
Researchers are looking for new treatments for pain. While there are many approved treatments for pain, the treatments do not work well for everyone. People can also become addicted to certain pain medicines.
- Trial name
- NCT07862595
- Testing
- MK-6916, Hydrocodone/acetaminophen (HB/APAP), Rescue Medication
- Volunteers
- 380 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of oxycodone 40 mg compared to an equivalent oral…
- Trial name
- NCT00853892
- Testing
- Controlled-Release Oxycodone Hydrochloride 40 mg tablet, OxyContin® 40 mg tablet
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Pain
A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers
This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 6- dosing period study to characterize the pharmacokinetics of oxycodone (process by which oxycodone is…
- Trial name
- NCT01552863
- Testing
- Oxycodone
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the safety profile of orally administered tapentadol ER dosages of 100 to 250 mg twice daily in patients with chronic, painful diabetic peripheral neuropathy (DPN) over long-term exposure…
- Trial name
- NCT01063868
- Testing
- Tapentadol extended release (ER), Oxycodone controlled release (CR)
- Where
- 23 sites in United States
- Volunteers
- 47 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Cancer, Pain
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
- Trial name
- NCT01885182
- Testing
- Oxycodone/Naloxone, Oxycodone
- Where
- 28 sites in China
- Volunteers
- 232 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Healthy
To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) relative to the original OxyContin® (OXY) formulation (80 mg) in the fed state.
- Trial name
- NCT01101178
- Testing
- Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP
Cancer, Pain
A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain
This study is to evaluate the efficacy and safety of a titration method by selects 10 mg control-released (CR) oxycodone tablet as background drug in combined with immediate-released (IR) oxycodone, compared to conventional…
- Trial name
- NCT03176199
- Testing
- Oxycodone
- Where
- 4 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taiwan Mundipharma Pharmaceuticals Ltd.
Osteoarthritis, Hip, Osteoarthritis, Knee
A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain
The purpose of this study is to evaluate the safety profile of tapentadol (CG5503) PR at doses of 100 mg - 250 mg administered twice daily over a maximum one year period to patients with at least a 3-month history of low back…
- Conditions
- Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
- Trial name
- NCT00361504
- Testing
- Oxycodone CR, Tapentadol (CG5503) ER
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,123 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.